These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 21999224)

  • 21. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.
    Nagstrup AH
    Acta Ophthalmol; 2023 Dec; 101 Suppl 278():3-21. PubMed ID: 38037546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
    Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells.
    Paimela T; Ryhänen T; Kauppinen A; Marttila L; Salminen A; Kaarniranta K
    Mol Vis; 2012; 18():1189-96. PubMed ID: 22605930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation.
    Pauly A; Roubeix C; Liang H; Brignole-Baudouin F; Baudouin C
    Invest Ophthalmol Vis Sci; 2012 Dec; 53(13):8172-80. PubMed ID: 23150620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride.
    McCarey B; Edelhauser H
    J Ocul Pharmacol Ther; 2007 Oct; 23(5):445-51. PubMed ID: 17941807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost.
    Kumar S; Singh T; Ichhpujani P; Vohra S
    Rom J Ophthalmol; 2019; 63(3):249-256. PubMed ID: 31687627
    [No Abstract]   [Full Text] [Related]  

  • 27. From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability.
    Rossi GC; Scudeller L; Rolle T; Pasinetti GM; Bianchi PE
    Expert Opin Drug Saf; 2015 May; 14(5):619-23. PubMed ID: 25759110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
    Lopes JF; Hubatsch DA; Amaris P
    BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells.
    Kahook MY; Ammar DA
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):259-63. PubMed ID: 20565312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duration of IOP reduction with travoprost BAK-free solution.
    Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
    J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system.
    Yee RW; Norcom EG; Zhao XC
    Adv Ther; 2006; 23(4):511-9. PubMed ID: 17050493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
    Crichton AC; Vold S; Williams JM; Hollander DA
    Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of polyquaternium- and benzalkonium-chloride-preserved travoprost on ocular surfaces: an impression cytology study.
    Sezgin Akçay Bİ; Güney E; Bozkurt TK; Topal CS; Akkan JC; Ünlü C
    J Ocul Pharmacol Ther; 2014 Sep; 30(7):548-53. PubMed ID: 24901262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study.
    Tau J; Passerini MS; Del Papa M; Aguilar A; Berra A
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1941-1946. PubMed ID: 35015115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride.
    Whitson JT; Cavanagh HD; Lakshman N; Petroll WM
    Adv Ther; 2006; 23(5):663-71. PubMed ID: 17142200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions.
    Kumagami T; Wakiyama H; Kusano M; Kajiyama A; Miura Y; Uematsu M; Yoneda A; Kurihara J; Suzuma K; Kitaoka T
    J Ocul Pharmacol Ther; 2014 May; 30(4):340-5. PubMed ID: 24576066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects.
    Stewart WC; Stewart JA; Jenkins JN; Jackson AL
    J Glaucoma; 2003 Dec; 12(6):475-9. PubMed ID: 14646682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study.
    Pisella PJ; Debbasch C; Hamard P; Creuzot-Garcher C; Rat P; Brignole F; Baudouin C
    Invest Ophthalmol Vis Sci; 2004 May; 45(5):1360-8. PubMed ID: 15111589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.